Requires health insurance and Medicaid coverage for testing and treatments to slow progression of Alzheimer's disease and related disorders.

This bill requires New Jersey’s health insurance plans and Medicaid to cover diagnostic testing and FDA-approved medications that can slow the progression of Alzheimer’s disease and related disorders. It ensures that these treatments are accessible to patients without requiring ‘step therapy,’ which often delays access to necessary medications. The bill aims to improve care for individuals affected by these conditions and potentially reduce long-term healthcare costs by delaying the need for more intensive care settings. It expands coverage for medications currently not included in state programs.